4//SEC Filing
TZIANABOS ARTHUR 4
Accession 0000950170-24-015944
CIK 0001661998other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 4:33 PM ET
Size
12.4 KB
Accession
0000950170-24-015944
Insider Transaction Report
Form 4
TZIANABOS ARTHUR
Director
Transactions
- Exercise/Conversion
Common Stock
2024-01-01+14,280→ 122,675 total - Exercise/Conversion
Common Stock
2024-01-01+19,140→ 141,815 total - Sale
Common Stock
2024-01-09$0.57/sh−13,037$7,445→ 128,778 total - Exercise/Conversion
Restricted Stock Units
2024-01-01−14,280→ 0 total→ Common Stock (14,280 underlying) - Exercise/Conversion
Restricted Stock Units
2024-01-01−19,140→ 19,720 total→ Common Stock (19,140 underlying)
Footnotes (5)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
- [F2]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs.
- [F3]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $0.5710 to $0.5712. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.
- [F4]The RSUs are fully vested and do not have an expiration date.
- [F5]The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date.
Documents
Issuer
Homology Medicines, Inc.
CIK 0001661998
Entity typeother
Related Parties
1- filerCIK 0001586226
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 4:33 PM ET
- Size
- 12.4 KB